Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial).
Amparo Garcia-Tejedor, Carlos Ortega-Exposito, Sira Salinas...
https://pubmed.ncbi.nlm.nih.gov/37621686/Actively Recruiting
Led by Hospital Universitari de Bellvitge · Updated on 2026-09-17
820
Participants Needed
61
Research Sites
104 weeks
Total Duration
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
CONDITIONS
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
A
Amparo Garcia-Tejedor, MDPhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital Universitari de Bellvitge
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants receive either axillary radiotherapy without lymph node removal or axillary lymph node dissection followed by radiotherapy to specific lymph node areas.
Regular visits as scheduled by the study
Duration - Up to 5 years
Participants are monitored for disease-free survival, overall survival, and lymphedema incidence for up to 5 years after diagnosis.
Periodic assessments over 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Amparo Garcia-Tejedor, Carlos Ortega-Exposito, Sira Salinas...
https://pubmed.ncbi.nlm.nih.gov/37621686/Hospital Universitari de Bellvitge
Lead Sponsor